CStone braves the HKEX with late-stage plans brew­ing for new­ly beefed up I/O pipeline

This May, when CStone bagged $260 mil­lion in what it said was the largest Se­ries B fund­ing in the his­to­ry of the Chi­nese bio­phar­ma in­dus­try, CEO Frank Jiang her­ald­ed the round as crit­i­cal for the com­pa­ny’s “cur­rent and near-term growth.” It quick­ly be­came clear how: With­in weeks, the fast-grow­ing Chi­nese im­muno-on­col­o­gy play­er sealed li­cens­ing deals with two ris­ing US biotech stars, di­ver­si­fy­ing the mol­e­c­u­lar tar­gets be­ing ad­dressed by its clin­i­cal pipeline, and poached sea­soned Gold­man Sachs health­care man­ag­ing di­rec­tor Richard Yeh to be its new CFO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.